Editors' ChoiceCancer Immunotherapy

Refining precision immunotherapy

See allHide authors and affiliations

Science Signaling  19 Jan 2021:
Vol. 14, Issue 666, eabg5661
DOI: 10.1126/scisignal.abg5661

Two studies show why some, but not all, MMR-deficient tumors are sensitive to immunotherapy.

View Full Text

Stay Connected to Science Signaling